Vera Therapeutics, Inc. (VERA)
$26.79-3.35%Close
SELLCRISIS · day 9
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.9B
- Beta
- 0.95
- P/E (TTM)
- -4.57
- Short % float
- 29.46%
- Days to cover
- 7.8
- SI change
- +1.2%
- 1W
- -8.94%
- 1M
- -21.32%
- vs SPY 1W
- -8.80%
- vs SPY 1M
- -23.83%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$82.37-4.89%
- ARQTBUYArcutis Biotherapeutics, Inc.$3.3BRECOVERYQ 11$26.58-0.50%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$12.08-3.30%
- ANABSELLAnaptysBio, Inc.$1.4BCRISISQ 25$45.95-0.98%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -1$10.82-2.53%
- ALMSSELLAlumis Inc.$884MCRISISQ 0$7.16-7.08%
- PHARSELLPharming Group N.V.$693MCRISISQ -1$9.79-1.77%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83-3.61%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 8
- GROWTH
- 45
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-50.5%
REV YoY-
ROE-84.1%
EPS YoY-
ROA-75.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-4.57
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B4.72
P/FCF-
EV/EBITDA-4.95
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E18.45
ALTMAN Z-
CURR RATIO10.92
ND/EBITDA-
BETA0.95
Company news
FAQ
- What is LOPJLB’s current signal on VERA?
- LOPJLB’s latest quantitative signal on Vera Therapeutics, Inc. (VERA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is VERA in?
- Vera Therapeutics, Inc. (VERA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Vera Therapeutics, Inc. (VERA) do?
- Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to tr…